Physician profile
Max A Schaefer
NPI 1922590652
$828.79
in general payments reported to CMS, 2019-2025
16 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.52 · 2023: $200 · 2024: $284 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $197.26 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $186.89 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $70.36 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Dexcom, INC. | $59.22 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $49.47 | 2023-2025 | |
| Lilly USA, LLC | $40.55 | 2023-2024 | Jardiance |
| Abbott Laboratories | $39.53 | 2025 | Freestyle Libre 3 |
| Indivior INC. | $38.60 | 2025 | Sublocade |
| Xeris Pharmaceuticals, INC. | $23.76 | 2025 | Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.16 | 2024 | Jardiance |
| Insulet Corporation | $19.87 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.20 | 2025 | Xifaxan |
| Boston Scientific Corporation | $18.72 | 2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $16.89 | 2023 | Opsumit, Uptravi |
| Endogastric Solutions, INC | $15.52 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.79 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.